Tag Archive for: T790M

Amivantamab in combination with Lazertinib showed efficacy in NSCLC

Amivantamab in combination with Lazertinib showed efficacy in NSCLC

Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer. The most frequent genetic mutation harboured in lung adenocarcinomas occurs in the epidermal growth factor receptor (EGFR), accounting for 40-55% in Asian patients.

Osimertinib in patients with T790M-positive advanced non-small cell lung cancer and brain metastases (AURA3)

Osimertinib is active in the second-line treatment of patients with T790M-positive advanced non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases, as reported by the investigators of the Phase III AURA3 study.